ONA, OTCQBNANF) said on Wednesday it has received approval from Nova Scotia's Health Research Ethics Board to proceed with a pilot human clinical trial of its gold nanorod-based cancer treatment in patients with late-stage melanoma. The multi-centre trial involving up to 40 patients will test Sona's Targeted Hyperthermia Therapy (THT), which uses biocompatible gold nanorods designed to destroy cancer cells with localized heat. 